MoneyWorks4Me

India Ratings assigns A1+ rating to Cipla’s short-term debt programme

30 Apr 2013 Evaluate

Credit rating agency, India Ratings & Research has assigned A1+ rating to Cipla’s Rs 1,000 crore commercial paper/ short-term debt programme.

The rating reflects the company’s comfortable credit profile with financial leverage (adjusted debt net of cash/EBITDAR) below 1.5x over FY09-FY12 (year end March). The low level of financial leverage provides the company enough headroom to take on additional debt.

Cipla focuses on development of new formulations and has a wide range of pharmaceutical products. It offers prescription drugs, bulk drugs, animal products and pesticides. It also offers a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products.

Cipla Share Price

1385.30 -10.65 (-0.76%)
08-Sep-2026 12:43 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1890.95
Dr. Reddys Labs. 1150.90
Cipla 1385.30
Lupin 2110.40
Zydus Lifesciences 1155.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: